Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cost of Revenue (2020 - 2023)

Historic Cost of Revenue for ADC Therapeutics (ADCT) over the last 4 years, with Q3 2023 value amounting to $13.7 million.

  • ADC Therapeutics' Cost of Revenue rose 96023.17% to $13.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $517.8 million, marking a year-over-year increase of 1255717.7%. This contributed to the annual value of $4.6 billion for FY2022, which is 32871490358.94% up from last year.
  • ADC Therapeutics' Cost of Revenue amounted to $13.7 million in Q3 2023, which was up 96023.17% from $14.5 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Cost of Revenue peaked at $489.0 million during Q4 2022, and registered a low of $770.0 during Q4 2021.
  • For the 4-year period, ADC Therapeutics' Cost of Revenue averaged around $44.9 million, with its median value being $1.8 million (2022).
  • Examining YoY changes over the last 5 years, ADC Therapeutics' Cost of Revenue showed a top increase of 6350639350.65% in 2022 and a maximum decrease of 9619.73% in 2022.
  • Over the past 4 years, ADC Therapeutics' Cost of Revenue (Quarter) stood at $2.6 million in 2020, then plummeted by 99.97% to $770.0 in 2021, then surged by 63506393.51% to $489.0 million in 2022, then crashed by 97.19% to $13.7 million in 2023.
  • Its last three reported values are $13.7 million in Q3 2023, $14.5 million for Q2 2023, and $590000.0 during Q1 2023.